<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res</journal-id><journal-title-group><journal-title>Breast Cancer Research : BCR</journal-title></journal-title-group><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4231907</article-id><article-id pub-id-type="publisher-id">bcr1227</article-id><article-id pub-id-type="doi">10.1186/bcr1227</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Rodenhuis</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Bontenbal</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Beex</surname><given-names>LVAM</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Smit</surname><given-names>WM</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Nooij</surname><given-names>MA</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Voest</surname><given-names>EE</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Wall</surname><given-names>E van der</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Hupperets</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Tinteren</surname><given-names>Harm van</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Peterse</surname><given-names>HL</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Vijver</surname><given-names>MJ van de</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Vries</surname><given-names>EGE de</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A13"><collab>for the Netherlands Working Party on Autologous Transplantation in Solid Tumors</collab></contrib></contrib-group><aff id="I1"><label>1</label>Netherlands Cancer Institute, Amsterdam, The Netherlands</aff><aff id="I2"><label>2</label>Erasmus Medical Center/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands</aff><aff id="I3"><label>3</label>University Hospital Nijmegen, The Netherlands</aff><aff id="I4"><label>4</label>Medical Hospital Twente, Enschede, The Netherlands</aff><aff id="I5"><label>5</label>University Medical Center, Leiden, The Netherlands</aff><aff id="I6"><label>6</label>University Medical Center, Utrecht, The Netherlands</aff><aff id="I7"><label>7</label>Free University Hospital, Amsterdam, The Netherlands</aff><aff id="I8"><label>8</label>University Hospital, Maastricht, The Netherlands</aff><aff id="I9"><label>9</label>University Hospital Groningen, Groningen, The Netherlands</aff><pub-date pub-type="ppub"><year>2005</year></pub-date><pub-date pub-type="epub"><day>27</day><month>5</month><year>2005</year></pub-date><volume>7</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">VI Madrid Breast Cancer Conference: Changes in the treatment of breast cancer</named-content></supplement><fpage>S23</fpage><lpage>S23</lpage><conference><conf-date>1-3 June 2005</conf-date><conf-name>VI Madrid Breast Cancer Conference: Changes in the treatment of breast cancer</conf-name><conf-loc>Madrid, Spain</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The role of high-dose chemotherapy in the adjuvant treatment of high-dose breast cancer has not been established. Results have been reported from six randomized studies with a symmetrical study design (Table <xref ref-type="table" rid="T1">1</xref>). All show a lower relapse rate in the high-dose arm, but in only one study was this result statistically significant.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Randomized studies evaluating the role of high-dose chemotherapy in high-risk breast cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Author</th><th align="center">Patients</th><th align="center">Selection</th><th align="center">Conventional arm</th><th align="center">High-dose arm</th><th align="center">RFS analysis</th></tr></thead><tbody><tr><td align="left">Rodenhuis [1]</td><td align="center">885</td><td align="center">4<sup>+ </sup>nodes</td><td align="center">5&#x000d7;FEC</td><td align="center">4&#x000d7;FEC - CTC</td><td align="center">HD better (<italic>P </italic>= 0.08)</td></tr><tr><td align="left">Peters [2]</td><td align="center">785</td><td align="center">10<sup>+ </sup>nodes</td><td align="center">4&#x000d7;CAF + ID-CPB</td><td align="center">4&#x000d7;CAF + HD-CPB</td><td align="center">No difference, HD fewer relapses</td></tr><tr><td align="left">Tallman [3]</td><td align="center">540</td><td align="center">10<sup>+ </sup>nodes</td><td align="center">6&#x000d7;CAF</td><td align="center">6&#x000d7;CAF + CT</td><td align="center">No difference, HD fewer relapses</td></tr><tr><td align="left">Roch&#x000e9;</td><td align="center">314</td><td align="center">8<sup>+ </sup>nodes</td><td align="center">4&#x000d7;FEC</td><td align="center">4&#x000d7;FEC + CMA</td><td align="center">HD better (<italic>P </italic>= 0.002)</td></tr><tr><td align="left">Tokuda</td><td align="center">97</td><td align="center">10<sup>+ </sup>nodes</td><td align="center">6&#x000d7;CAF</td><td align="center">6&#x000d7;CAF + CT</td><td align="center">HD better (NS)</td></tr><tr><td align="left">Rodenhuis</td><td align="center">81</td><td align="center">Infraclav biopsy</td><td align="center">4&#x000d7;FEC</td><td align="center">4&#x000d7;FEC + CTC</td><td align="center">No difference, HD less relapses</td></tr></tbody></table><table-wrap-foot><p>CAF, cyclophosphamide, doxorubicin, fluorouracil; CMA, cyclophosphamide, mitoxantrone and melphalan; CT, cyclophosphamide and thiotepa; CTC, cyclophosphamide, thiotepa and carboplatin; FEC, fluorouracil, epirubicin, cyclophosphamide; nodes, tumor-positive axillary lymph nodes; HD-CPB, high-dose cyclophosphamide, cisplatin and BCNU; ID-CPB, intermediate-dose cyclophosphamide, cisplatin and BCNU.</p></table-wrap-foot></table-wrap></sec><sec sec-type="methods"><title>Methods</title><p>Patients below 56 years of age who had undergone surgery for stage II or III breast cancer were eligible if they had at least four tumor-positive axillary lymph nodes. Patients in the conventional dose (CD) arm received five courses of FEC (fluorouracil 500 mg/m<sup>2</sup>, epirubicin 90 mg/m<sup>2 </sup>and cyclophosphamide 500 mg/m<sup>2</sup>; every 3 weeks) followed by radiation therapy and tamoxifen. The high-dose (HD) arm was identical, except that high-dose chemotherapy (CTC [cyclophosphamide 6 g/m<sup>2</sup>, thiotepa 480 mg/m<sup>2 </sup>and carboplatin 1600 mg/m<sup>2</sup>]) with peripheral blood progenitor cell reinfusion was given instead of the fifth FEC course.</p></sec><sec sec-type="results"><title>Results</title><p>Between August 1993 and July 1999, 885 patients with primary breast cancer and four or more tumor-positive lymph nodes were randomized in 10 Dutch centers in a study of high-dose chemotherapy. The results of this study at 57 months of follow-up have now been updated at 87 months. In a pathology review, 621 tumor samples were shown to be HER2/neu-negative (either 0+ at immunohistochemistry or negative at <italic>in situ </italic>hybridization). Patients with HER2/neu-negative disease had a 5-year RFS of 72% following HD and of 59% after CD (<italic>P </italic>= 0.002). Overall survival in the HD group was 78% at 5 years versus 71% for the CD group (<italic>P </italic>= 0.02). Young age and low malignancy grade were associated with a relative benefit for HD (tests for interactions: <italic>P </italic>= 0.04 and <italic>P </italic>= 0.0057, respectively). The treatment-related mortality in the high-dose chemotherapy arm was 1%. An equal number of second malignancies were observed in both arms.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Although the subgroup analysis of HER2/neu-negative disease was not planned in the original protocol, these findings are consistent with findings from other studies [<xref ref-type="bibr" rid="B4">4</xref>]. The marked efficacy of HD therapy in HER2/neu-negative breast cancer may have been masked in this and in other studies by its disadvantage in the HER2/neu-positive group, which may have benefited from a higher dose of anthracycline-dose in the control arm. High-dose alkylating chemotherapy is a viable option for high-risk breast cancer patients with HER2/neu-negative disease.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Rodenhuis</surname><given-names>S</given-names></name><name><surname>Bontenbal</surname><given-names>M</given-names></name><name><surname>Beex</surname><given-names>LV</given-names></name><etal/><article-title>High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa022794</pub-id><pub-id pub-id-type="pmid">12840087</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Peters</surname><given-names>WP</given-names></name><name><surname>Rosner</surname><given-names>GL</given-names></name><name><surname>Vredenburgh</surname><given-names>JJ</given-names></name><etal/><article-title>Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB SWOG 9114, and NCIC MA-13</article-title><source>J Clin Oncol </source><year>9082</year><volume>23</volume><fpage>2191</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.10.202</pub-id><pub-id pub-id-type="pmid">15767638</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>Robert</surname><given-names>NJ</given-names></name><etal/><article-title>Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer</article-title><source>N Engl J Med </source><year>2003</year><volume>349</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030684</pub-id><pub-id pub-id-type="pmid">12840088</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Nieto</surname><given-names>Y</given-names></name><name><surname>Nawaz</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>RB</given-names></name><etal/><article-title>Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>707</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.3.707</pub-id><pub-id pub-id-type="pmid">11821452</pub-id></mixed-citation></ref></ref-list></back></article>